Eli Lilly & Co
A pharmaceutical company whose medicines treat diabetes and obesity (Mounjaro, Zepbound, Trulicity, Jardiance), cancer (Verzenio, Cyramza), immunology conditions, and neurological diseases like migraine and Alzheimer's. Founded in 1876 in Indianapolis by Colonel Eli Lilly, a Civil War veteran and chemist, the firm started as a wholesale drug maker. Its founder opened the lab partly to fight the "snake oil" patent medicines of his day, vowing to sell only high-quality remedies recommended by physicians.
Sold 8.39M
Granted 220.5K · Bought 1.6K
Granted 78.8K · Bought 1.0K · Sold 5.0K
Granted 1.1K · Bought 1.6K
Granted 19.6K
Granted 28.8K
Granted 1.4K · Bought 758
Granted 40.5K
Granted 24.1K
Granted 4.2K
Granted 24.1K · Bought 1.0K
Granted 26.4K · Sold 5.0K
Granted 2.9K · Sold 7.1K
Granted 24.7K
Granted 852.86
Granted 852.86
Granted 1.5K
Granted 335
Granted 5.7K · Bought 715
Granted 12.6K
Granted 866.28
Granted 852.86 · Bought 200
Granted 951 · Sold 1.1K
Granted 637.53
Granted 8.2K · Sold 7.8K
Granted 1.6K
Granted 1.1K
Granted 1.1K · Bought 117
Granted 1.2K
Granted 952
Granted 233.27
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lilly Endowment IncFormer 10% Shareholder · 736 transactions | -8.4% | 91.88M | — | — | 8.39M |
| Ricks David APresident, Chair, and CEO, Director · 14 transactions | — | 708.8K | 220.5K | 1.6K | — |
| Skovronsky DanielEVP, CS&PO & Pres. LRL · 17 transactions | — | 235.7K | 78.8K | 1.0K | 5.0K |
| Fyrwald J ErikDirector · 27 transactions | +5.9% | 75.4K | 1.1K | 1.6K | — |
| White Anne E.EVP & Pres, Lilly Neuroscience · 6 transactions | +28.1% | 74.2Kas of Feb 2025 | 19.6K | — | — |
| Jonsson PatrikEVP & President, LLY Int'l · 9 transactions | +63.5% | 61.3K | 28.8K | — | — |
| Alvarez RalphDirector · 38 transactions | — | 56.5K | 1.4K | 758 | — |
| Hakim AnatEVP, GC & Secretary · 11 transactions | — | 55.6K | 40.5K | — | — |
| Hernandez EdgardoEVP & Pres., Mfg. Operations · 12 transactions | +69.4% | 47.0K | 24.1K | — | — |
| Ashkenazi AnatEVP & CFO · 1 transaction | +11% | 42.5Kas of Feb 2024 | 4.2K | — | — |
| Van Naarden JacobEVP,Pres LLY Oncology&HdCorpBD · 11 transactions | — | 40.6K | 24.1K | 1.0K | — |
| Yuffa IlyaEVP&Pres, LLY USA&Global Capab · 12 transactions | +129.7% | 29.8K | 26.4K | — | 5.0K |
| Norton JohnaEVP, Global Quality · 4 transactions | -14.4% | 27.7Kas of Jun 2024 | 2.9K | — | 7.1K |
| Rau DiogoEVP & CIDO · 8 transactions | +146.8% | 26.4K | 24.7K | — | — |
| Baicker KatherineDirector · 3 transactions | +6.4% | 23.5K | 852.86 | — | — |
| Kaelin William G JrDirector · 3 transactions | +6.7% | 21.8K | 852.86 | — | — |
| Luciano Juan RDirector · 37 transactions | +12% | 16.9K | 1.5K | — | — |
| Runge Marschall SDirector · 1 transaction | +3.1% | 16.6Kas of Nov 2023 | 335 | — | — |
| Montarce LucasEVP & CFO · 7 transactions | — | 16.3K | 5.7K | 715 | — |
| Dozier EricEVP, Chief People Officer · 13 transactions | +93.2% | 14.8K | 12.6K | — | — |
| Custer Kenneth L.EVP & President, Card Met Hlth · 3 transactions | — | 10.2K | 866.28 | — | — |
| Jackson JamereDirector · 4 transactions | +15.1% | 9.6K | 852.86 | 200 | — |
| Weems AlonzoEVP, ERM & CECO · 3 transactions | -10.7% | 8.0Kas of Feb 2024 | 951 | — | 1.1K |
| Walker KarenDirector · 2 transactions | +13.3% | 6.2Kas of Nov 2024 | 637.53 | — | — |
| Zakrowski Donald ASVP, Finance, & CAO · 16 transactions | -25.8% | 5.3K | 8.2K | — | 7.8K |
| Brown Adrienne SEVP, President LLY Imm · 3 transactions | — | 5.1K | 1.6K | — | — |
| Johnson Kimberly HDirector · 19 transactions | +51.1% | 3.3K | 1.1K | — | — |
| Sulzberger GabrielleDirector · 38 transactions | +76.8% | 3.0K | 1.1K | 117 | — |
| Hedley Mary LynneDirector · 31 transactions | +110.8% | 2.4K | 1.2K | — | — |
| Seymour MelissaEVP, Global Quality · 2 transactions | — | 525.08as of Aug 2025 | 952 | — | — |
| Moeller Jon RDirector · 1 transaction | — | 304.27 | 233.27 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -8.41M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.